Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Allergan PLC (AGN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Allergan PLC is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and OTC pharmaceutical products. Allergan PLC has a market cap of $46.91 billion; its shares were traded at around $139.07 with and P/S ratio of 2.97. The dividend yield of Allergan PLC stocks is 2.09%.


For the last quarter Allergan PLC reported a revenue of $4.1 billion, compared with the revenue of $4.3 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $15.8 billion, a decrease of 1% from the previous year. For the last five years Allergan PLC had an average revenue growth rate of 44.3% a year.

The reported loss per diluted share was $15.26 for the year. The Allergan PLC had an operating margin of 1.62%, compared with the operating margin of -3.4% a year before. The 10-year historical median operating margin of Allergan PLC is -0.89%. The profitability rank of the company is 4 (out of 10).

At the end of the fiscal year, Allergan PLC has the cash and cash equivalents of $880.4 million, compared with $1.8 billion in the previous year. The company had no long term debt, compared with $25.8 billion in the previous year. The company's operating income of cannot cover its interest payment during the last fiscal year. Allergan PLC has a financial strength rank of 5 (out of 10).

At the current stock price of $139.07, Allergan PLC is traded at 17.6% premium to its historical median P/S valuation band of $118.30. The P/S ratio of the stock is 2.97, while the historical median P/S ratio is 2.53. The stock lost 14.61% during the past 12 months.

For the complete 20-year historical financial data of AGN, click here.

This article first appeared on GuruFocus.


Advertisement